Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/27168
Type
ArticleCopyright
Restricted access
Embargo date
2023-01-01
Collections
Metadata
Show full item record
REDUCING THE GLOBAL BURDEN OF HTLV-1 INFECTION: AN AGENDA FOR RESEARCH AND ACTION
Author
Willems, Luc
Hasegawa, Hideki
Accolla, Roberto
Bangham, Charles
Bazarbachi, Ali
Bertazzoni, Umberto
Proietti, Anna Barbara de Freitas Carneiro
Cheng, Hua
Bianchi, Luigi Chieco
Ciminale, Vincenzo
Reis, Jordana Grazziela Alves Coelho dos
Esparza, Jose
Gallo, Robert C.
Gessain, Antoine
Gotuzzo, Eduardo
Hall, William
Harford, Joseph
Hermine, Olivier
Jacobson, Steven
Macchi, Beatrice
Macpherson, Calum
Mahieux, Renaud
Matsuoka, Masao
Murphy, Edward
Peloponese, Jean-Marie
Simon, Viviana
Tagaya, Yutaka
Taylor, Graham P
Watanabe, Toshiki
Yamano, Yoshihisa
Hasegawa, Hideki
Accolla, Roberto
Bangham, Charles
Bazarbachi, Ali
Bertazzoni, Umberto
Proietti, Anna Barbara de Freitas Carneiro
Cheng, Hua
Bianchi, Luigi Chieco
Ciminale, Vincenzo
Reis, Jordana Grazziela Alves Coelho dos
Esparza, Jose
Gallo, Robert C.
Gessain, Antoine
Gotuzzo, Eduardo
Hall, William
Harford, Joseph
Hermine, Olivier
Jacobson, Steven
Macchi, Beatrice
Macpherson, Calum
Mahieux, Renaud
Matsuoka, Masao
Murphy, Edward
Peloponese, Jean-Marie
Simon, Viviana
Tagaya, Yutaka
Taylor, Graham P
Watanabe, Toshiki
Yamano, Yoshihisa
Affilliation
University of Liege. Belgium/Chairs of the HTLV Taskforce of the Global Virus Network. USA
National Institute of Infectious Diseases. Tokyo, Japan/Chairs of the HTLV Taskforce of the Global Virus Network. USA
University of Insubria. Varese, Italy
Imperial College. London, UK
American University of Beirut. Beirut, Lebanon
University of Verona. Verona, Italy
Fundaçao Hemominas. Belo Horizonte, MG, Brazil
Institute of Human Virology. Baltimore, USA
University of Padova, Padova. Italy
University of Padova, Padova. Italy
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brazil
Institute of Human Virology. Baltimore, USA
Institute of Human Virology. Baltimore, USA
Institut Pasteur. Paris, France
Tropical Medical Institute Alexander von Humboldt. Lima, Peru
Centre for Research in Infectious Disease. Dublin, Ireland
National Cancer Institute. NIH. Bethesda, USA
Hospital Necker. Paris, France
National Institute of Neurological Disorders and Stroke. NIH. Bethesda, USA
University of Rome Tor Vergata. Rome, Italy
St. George's University. Grenada
Ecole Normale Superieure de Lyon. Lyon, France
Kyoto University. Kyoto, Japan
University of California. San Francisco, CA, USA
University of Montpellier. Montpellier, France
Icahn School of Medicine at Mount Sinai. New York, USA
Institute of Human Virology. Baltimore, USA
Imperial College. London, UK
University of Tokyo. Tokyo, Japan
St. Marianna University School of Medicine. Kanagawa, Japan
National Institute of Infectious Diseases. Tokyo, Japan/Chairs of the HTLV Taskforce of the Global Virus Network. USA
University of Insubria. Varese, Italy
Imperial College. London, UK
American University of Beirut. Beirut, Lebanon
University of Verona. Verona, Italy
Fundaçao Hemominas. Belo Horizonte, MG, Brazil
Institute of Human Virology. Baltimore, USA
University of Padova, Padova. Italy
University of Padova, Padova. Italy
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brazil
Institute of Human Virology. Baltimore, USA
Institute of Human Virology. Baltimore, USA
Institut Pasteur. Paris, France
Tropical Medical Institute Alexander von Humboldt. Lima, Peru
Centre for Research in Infectious Disease. Dublin, Ireland
National Cancer Institute. NIH. Bethesda, USA
Hospital Necker. Paris, France
National Institute of Neurological Disorders and Stroke. NIH. Bethesda, USA
University of Rome Tor Vergata. Rome, Italy
St. George's University. Grenada
Ecole Normale Superieure de Lyon. Lyon, France
Kyoto University. Kyoto, Japan
University of California. San Francisco, CA, USA
University of Montpellier. Montpellier, France
Icahn School of Medicine at Mount Sinai. New York, USA
Institute of Human Virology. Baltimore, USA
Imperial College. London, UK
University of Tokyo. Tokyo, Japan
St. Marianna University School of Medicine. Kanagawa, Japan
Abstract
Even though an estimated 10e20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort hás been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections.
Share